1,3-Bis(2-ethylhexyl)-5-methylhexahydropyrimidin-5-amine

Catalog No. :
ACURZP471
CAS No. :
141-94-6
Molecular Formula :
C21H45N3
Molecular Weight :
339.61

IUPAC Name:1,3-bis(2-ethylhexyl)-5-methylhexahydropyrimidin-5-amine

1,3-Bis(2-ethylhexyl)-5-methylhexahydropyrimidin-5-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$58.00Login to see priceIn stockInquiry
1g98%$70.00Login to see priceIn stockInquiry
5g98%$111.00Login to see priceIn stockInquiry
25g98%$536.00Login to see priceIn stockInquiry
100g98%$1658.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1,3-Bis(2-ethylhexyl)-5-methylhexahydropyrimidin-5-amine
IUPAC Name1,3-bis(2-ethylhexyl)-5-methylhexahydropyrimidin-5-amine
MDL No.MFCD00010428
Molecular FormulaC21H45N3
Molecular Weight339.61
SMILESNC1(CN(CN(C1)CC(CCCC)CC)CC(CCCC)CC)C
InChI KeyDTOUUUZOYKYHEP-UHFFFAOYSA-N
Synonymhexetidine | 141-94-6 | Oraldene | Sterisil | Hexoral | Glypesin | Hextril | Elsix | Sterilate | Triocil | Triscol | Collu hextril | Duranil Aerosol | Hexetidinum | Steri/Sol | NSC-17764 | 5-Amino-1,3-bis(2-ethylhexyl)hexahydro-5-methylpyrimidine | NSC 17764 | 1,3-bis(2-ethylhexyl)-5-methyl
CAS No.141-94-6
PubChem CID3607

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACURZP471 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACURZP471 route product structure diagram
    ACURZP471141-94-6 In Stock
Inquiry

2. ACURZP471 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACURZP471 route product structure diagram
    ACURZP471141-94-6 In Stock
Inquiry

Comments (0)